Organon and Lilly expand deal for migraine treatment to new markets
Organon and Eli Lilly and Company have broadened their commercial agreement under which the former will be the sole distributor…
Central Nervous System
-
-
UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease
The Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved the use of BioArctic and Eisai’s…
-
FDA rejects Lykos MDMA therapy, asks for another Phase III trial
Lykos Therapeutics’ midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD) has suffered another setback after the US Food and Drug…
-
FDA approves Servier’s VORANIGO for IDH-mutant Grade 2 glioma
The US Food and Drug Administration (FDA) has approved Servier's VORANIGO for patients aged 12 years and above with Grade…
-
Genentech and Sangamo to develop neurodegenerative disease therapies
Sangamo Therapeutics has signed a global licence agreement with Roche Group member Genentech for the development of genomic medicines to…
-
Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year
The US Food and Drug Administration (FDA) has accepted Vertex Pharmaceuticals’ completed new drug application (NDA) submission for suzetrigine, as…
-
Study finds semaglutide decreases tobacco-related healthcare
A new study suggests that semaglutide use could reduce the prevalence of several indicators associated with tobacco use disorder. Researchers…
-
Collegium buys Ironshore for $525m and enter ADHD market
Collegium Pharmaceuticals has signed a definitive agreement to acquire Ironshore Therapeutics in a bid to expand its portfolio beyond pain…
-
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
The European Medicines Agency (EMA) has halted Eisai and Biogen’s expansion plan to launch its Alzheimer’s disease therapy Leqembi (lecanemab)…
-
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day…
